biologic

Ngenla

somatrogon-ghla

Loss of exclusivityJune 2035projected — 12-year biologic exclusivity estimate
CompanyPfizer Ireland Pharmaceuticals Unlimited Company

Drug detail

Brand nameNgenla
Active ingredientsomatrogon-ghla
Strength24MG/1.2ML (20MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ngenla patent cliff — loss of exclusivity June 2035 | CliffBio